ライブ
FierceBiotechFoundation Medicine tallies FDA nod to pair its blood test with Pfizer’s prostate cancer comboFierceBiotechNew heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cellsEndpoints NewsLilly gives hospitals deadline to comply with 340B claims data policyEndpoints NewsFDA details flexibilities for new cell and gene therapies to leverage past dataEndpoints NewsAnti-aging biotech NewLimit raises $435M at $3B+ valuationBioPharma DiveEli Lilly issues data sharing ultimatum to 340B hospitalsFierceBiotechASCO: Roche, head held high, details oral SERD's first-line flop in breast cancerBioPharma DiveFulcrum exploring a potential sale after FDA sidelined its sickle cell drugEndpoints NewsWhat’s next for VEGF? #ASCO26 offered clues, but answers will have to waitBioWorldLongbio to raise HK$1.4B in Hong Kong IPO for immunology workBioWorldADCs, multispecific antibodies anchor $10B Pfizer-Innovent dealBioWorldChina launches long-awaited drug data protection rules
eLife 2026年6月2日

Correction: Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor

Correction: Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibito...

本文は利用できません。元の情報源をご確認ください。